All the news

Ministers of Health and Economy inaugurate the expansion of the R&D Centre of Bluepharma

17.03.2017 in Bluepharma

An investment of 2 million euros

On 17 March 2017, the expansion of Bluepharma’s Research and Development Centre was inaugurated by the Minister of Health, Adalberto Campos Fernandes, and the Minister of Economy, Manuel Caldeira Cabral.

According to the Chairman of Bluepharma, Paulo Barradas Rebelo, “the 2 million euro investment in this expansion resulted in the hiring of 50 new employees, namely newly graduates and PhDs, particularly in Research & Development".

“We realise the importance of fostering the generics market in Portugal. Today generics are safe and quality medicines that do two things: contribute to the strategic sustainability of the health system, and especially treat households in safe and quality conditions, increasing their available income”, the Minister of Health, Adalberto Campos Fernandes, highlighted.

“Bluepharma is a good example of a company that managed to transform a multinational company in Portugal into a Portuguese multinational present worldwide”, stated the Minister of Economy, Manuel Caldeira Cabral, adding, “In 2016, the Portuguese economy exported 1400 million euros in health products, while 8 years before it had exported 600 million. It is a remarkable growth achieved by the companies in the industry, a growth to which Bluepharma contributed with its innovation, its dynamics, 85% of exports and its presence in all markets”.

The expansion and conversion of the Research and Development Centre resulted in a modern lab for the development of cancer care. “Bluepharma has invested over 15 million euros in Research and Development (R&D) in the last three years. The ongoing focus on R&D is paramount for our strategy of sustained growth in the export of drugs to more demanding world markets – such as the USA and most European countries” says Paulo Barradas Rebelo. Furthermore, "In 2016, our export rate was approximately 85%. Every year Bluepharma invests 20 per cent of its turnover in research and development, a number that shows the group's commitment to being at the forefront of innovation".

The Chairman of Bluepharma highlighted further: “We have concentrated our research efforts on nanotechnology, oncology and biotechnology, where we have developed several projects in partnership with companies and national and international R&D reference centres”.

“At the same time, we have carried out several development activities of pharmaceutical formulations, analytical methods and manufacturing procedures, and stability and scaling up studies in view of developing new generic medicines for more challenging treatment areas, namely oncology”, Paulo Barradas concluded.